Erratum: A dose-dependent plasma signature of the safety and immunogenicity of the rVSV-Ebola vaccine in Europe and Africa (Science Translational Medicine DOI: 10.1126/scitranslmed.aaj1701);A dose-dependent plasma signature of the safety and immunogenicity of the rVSV-Ebola vaccine in Europe and Africa

Science Translational Medicine

Volumn 9, Issue 385, 2017, Pages

  Huttner, Angela ^a   Combescure, Christophe ^a   Grillet, Stéphane ^b   Haks, Mariëlle C ^c   Quinten, Edwin ^c   Modoux, Christine ^a   Agnandji, Selidji Todagbe ^d,e   Brosnahan, Jessica ^d   Dayer, Julie Anne ^a   Harandi, Ali M ^f   Kaiser, Laurent ^a   Medaglini, Donata ^g,h   Monath, Tom ⁱ   Roux Lombard, Pascale ^a   Kremsner, Peter G ^d,e   Ottenhoff, Tom H M ^c   Siegrist, Claire Anne ^a,b  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d German Center for Infection Research CERMEL   (Gabon)

^e UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^f UNIVERSITY OF GOTHENBURG   (Sweden)

^g UNIVERSITY OF SIENA   (Italy)

^h Sclavo Vaccines Association   (Italy)

ⁱ NewLink Genetics Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EBOLA VACCINE; IMMUNOGLOBULIN G; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; RECOMBINANT VESICULAR STOMATITIS VIRUS ZAIRE EBOLA VACCINE; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

AFRICA; ANTIBODY RESPONSE; ANTIBODY TITER; ARTHRALGIA; ARTICLE; CHILL; CLINICAL TRIAL; CYTOKINE RESPONSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; EUROPE; FATIGUE; FEVER; HEADACHE; HUMAN; HUMAN EXPERIMENT; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; INJECTION SITE PAIN; INNATE IMMUNITY; LOW DRUG DOSE; LYMPHOCYTOPENIA; MONOCYTOSIS; MYALGIA; NEUTROPENIA; NORMAL HUMAN; THROMBOCYTOPENIA; UPREGULATION; VACCINATION; VESICULOVIRUS; VIRUS LOAD; ZAIRE EBOLAVIRUS; BLOOD; EBOLA HEMORRHAGIC FEVER; FEMALE; IMMUNOLOGY; MACROPHAGE; MALE; METABOLISM;

AFRICA; EBOLA VACCINES; EUROPE; FEMALE; HEMORRHAGIC FEVER, EBOLA; HUMANS; MACROPHAGES; MALE;

EID: 85017538993     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aaz0296     Document Type: Erratum

References (64)

1. R. Kanapathipillai, A. M. Henao Restrepo, P. Fast, D. Wood, C. Dye, M.-P. Kieny, V. Moorthy, Ebola vaccine-An urgent international priority. N. Engl. J. Med. 371, 2249-2251 (2014).
2. M. Garbutt, R. Liebscher, V. Wahl-Jensen, S. Jones, P. Moller, R. Wagner, V. Volchkov, H.-D. Klenk, H. Feldmann, U. Stroher, Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J. Virol. 78, 5458-5465 (2004).
3. A. M. Henao-Restrepo, A. Camacho, I. M. Longini, C. H. Watson, W. J. Edmunds, M. Egger, M. W. Carroll, N. E. Dean, I. Diatta, M. Doumbia, B. Draguez, S. Duraffour, G. Enwere, R. Grais, S. Gunther, P. S. Gsell, S. Hossmann, S. V. Watle, M. K. Kondé, S. Kéïta, S. Kone, E. Kuisma, M. M. Levine, S. Mandal, T. Mauget, G. Norheim, X. Riveros, A. Soumah, S. Trelle, A. S. Vicari, J.-A. Røttingen, M.-P. Kieny, Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: Final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!). Lancet 389, 505-518 (2017).
4. J. A. Regules, J. H. Beigel, K. M. Paolino, J. Voell, A. R. Castellano, P. Muñoz, J. E. Moon, R. C. Ruck, J. W. Bennett, P. S. Twomey, R. L. Gutiérrez, S. A. Remich, H. R. Hack, M. L. Wisniewski, M. D. Josleyn, S. A. Kwilas, N. Van Deusen, O. T. Mbaya, Y. Zhou, D. A. Stanley, R. L. Bliss, D. Cebrik, K. S. Smith, M. Shi, J. E. Ledgerwood, B. S. Graham, N. J. Sullivan, L. L. Jagodzinski, S. A. Peel, J. B. Alimonti, J. W. Hooper, P. M. Silvera, B. K. Martin, T. P. Monath, W. J. Ramsey, C. J. Link, H. C. Lane, N. L. Michael, R. T. Davey Jr., S. J. Thomas; rVSVDG-ZEBOV-GP Study Group, A recombinant vesicular stomatitis virus ebola vaccine. N. Engl. J. Med. 376, 330-341 (2015).
5. S. T. Agnandji, A. Huttner, M. E. Zinser, P. Njuguna, C. Dahlke, J. F. Fernandes, S. Yerly, J.-A. Dayer, V. Kraehling, R. Kasonta, A. A. Adegnika, M. Altfeld, F. Auderset, E. B. Bache, N. Biedenkopf, S. Borregaard, J. S. Brosnahan, R. Burrow, C. Combescure, J. Desmeules, M. Eickmann, S. K. Fehling, A. Finckh, A. R. Goncalves, M. P. Grobusch, J. Hooper, A. Jambrecina, A. L. Kabwende, G. Kaya, D. Kimani, B. Lell, B. Lemaitre, A. W. Lohse, M. Massinga-Loembe, A. Matthey, B. Mordmuller, A. Nolting, C. Ogwang, M. Ramharter, J. Schmidt-Chanasit, S. Schmiedel, P. Silvera, F. R. Stahl, H. M. Staines, T. Strecker, H. C. Stubbe, B. Tsofa, S. Zaki, P. Fast, V. Moorthy, L. Kaiser, S. Krishna, S. Becker, M.-P. Kieny, P. Bejon, P. G. Kremsner, M. M. Addo, C.-A. Siegrist, Phase 1 trials of rVSV ebola vaccine in Africa and Europe. N. Engl. J. Med. 374, 1647-1660 (2016).
6. A. Huttner, J.-A. Dayer, S. Yerly, C. Combescure, F. Auderset, J. Desmeules, M. Eickmann, A. Finckh, A. R. Goncalves, J. W. Hooper, G. Kaya, V. Krahling, S. Kwilas, B. Lemaitre, A. Matthey, P. Silvera, S. Becker, P. E. Fast, V. Moorthy, M. P. Kieny, L. Kaiser, C.-A. Siegrist; VSV-Ebola Consortium, The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: A randomised double-blind, placebo-controlled phase 1/2 trial. Lancet Infect. Dis. 15, 1156-1166 (2015).
7. B. D. Lichty, A. T. Power, D. F. Stojdl, J. C. Bell, Vesicular stomatitis virus: Re-inventing the bullet. Trends Mol. Med. 10, 210-216 (2004).
8. E. Hastie, V. Z. Grdzelishvili, Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer. J. Gen. Virol. 93, 2529-2545 (2012).
9. P. R. A. Buijs, J. H. E. Verhagen, C. H. J. van Eijck, B. G. van den Hoogen, Oncolytic viruses: From bench to bedside with a focus on safety. Hum. Vaccin. Immunother. 11, 1573-1584 (2015).
10. D. Medaglini, A. M. Harandi, T. H. M. Ottenhoff, C. A. Siegrist; VSV-EBOVAC Consortium, Ebola vaccine R&D: Filling the knowledge gaps. Sci. Transl. Med. 7, 317ps24 (2015).
11. J. Melchjorsen, Learning from the messengers: Innate sensing of viruses and cytokine regulation of immunity-Clues for treatments and vaccines. Viruses 5, 470-527 (2013).
12. J. Melchjorsen, L. N. Sorensen, S. R. Paludan, Expression and function of chemokines during viral infections: From molecular mechanisms to in vivo function. J. Leukoc. Biol. 74, 331-343 (2003).
13. S. L. Bixler, A. J. Goff, The role of cytokines and chemokines in filovirus infection. Viruses 7, 5489-5507 (2015).
14. B. Escudero-Pérez, V. A. Volchkova, O. Dolnik, P. Lawrence, V. E. Volchkov, Shed GP of Ebola virus triggers immune activation and increased vascular permeability. PLOS Pathog. 10, e1004509 (2014).
15. A. Okumura, P. M. Pitha, A. Yoshimura, R. N. Harty, Interaction between Ebola virus glycoprotein and host Toll-like receptor 4 leads to induction of proinflammatory cytokines and SOCS1. J. Virol. 84, 27-33 (2010).
16. E. M. Leroy, S. Baize, V. E. Volchkov, S. P. Fisher-Hoch, M. C. Georges-Courbot, J. Lansoud-Soukate, M. Capron, P. Debré, J. B. McCormick, A. J. Georges, Human asymptomatic Ebola infection and strong inflammatory response. Lancet 355, 2210-2215 (2000).
17. L. Hill-Batorski, P. Halfmann, A. Marzi, T. J. S. Lopes, G. Neumann, H. Feldmann, Y. Kawaoka, Loss of interleukin 1 receptor antagonist enhances susceptibility to Ebola virus infection. J. Infect. Dis. 212 (Suppl. 2), S329-S335 (2015).
18. A. K. McElroy, B. R. Erickson, T. D. Flietstra, P. E. Rollin, S. T. Nichol, J. S. Towner, C. F. Spiropoulou, Ebola hemorrhagic fever: Novel biomarker correlates of clinical outcome. J. Infect. Dis. 210, 558-566 (2014).
19. O. Martinez, J. C. Johnson, A. Honko, B. Yen, R. S. Shabman, L. E. Hensley, G. G. Olinger, C. F. Basler, Ebola virus exploits a monocyte differentiation program to promote its entry. J. Virol. 87, 3801-3814 (2013).
20. D. Bußfeld, M. Nain, P. Hofmann, D. Gemsa, H. Sprenger, Selective induction of the monocyte-Attracting chemokines MCP-1 and IP-10 in vesicular stomatitis virus-infected human monocytes. J. Interferon Cytokine Res. 20, 615-621 (2000).
21. K. Athearn, C. J. Sample, B. E. Barefoot, K. L. Williams, E. A. Ramsburg, Acute reactogenicity after intramuscular immunization with recombinant vesicular stomatitis virus is linked to production of IL-1b. PLOS ONE 7, e46516 (2012).
22. U. T. Hacker, T. Jelinek, S. Erhardt, A. Eigler, G. Hartmann, H. D. Nothdurft, S. Endres, In vivo synthesis of tumor necrosis factor-A in healthy humans after live yellow fever vaccination. J. Infect. Dis. 177, 774-778 (1998).
23. J.-S. Zhang, Q.-M. Zhao, S.-Q. Zuo, N. Jia, X.-F. Guo, Cytokine and chemokine responses to Japanese encephalitis live attenuated vaccine in a human population. Int. J. Infect. Dis. 16, e285-e288 (2012).
24. U.S. Food and Drug Administration (FDA), Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials (FDA, 2007); www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm091977.pdf.
25. M. C. Haks, J. J. Goeman, C. Magis-Escurra, T. H. M. Ottenhoff, Focused human gene expression profiling using dual-color reverse transcriptase multiplex ligation-dependent probe amplification. Vaccine 33, 5282-5288 (2015).
26. P. Becquart, N. Wauquier, T. Mahlakõiv, D. Nkoghe, C. Padilla, M. Souris, B. Ollomo, J.-P. Gonzalez, X. De Lamballerie, M. Kazanji, E. M. Leroy, High prevalence of both humoral and cellular immunity to Zaire ebolavirus among rural populations in Gabon. PLOS ONE 5, e9126 (2010).
27. R. T. Heffernan, B. Pambo, R. J. Hatchett, P. A. Leman, R. Swanepoel, R. W. Ryder, Low seroprevalence of IgG antibodies to Ebola virus in an epidemic zone: Ogooué-Ivindo region, Northeastern Gabon, 1997. J. Infect. Dis. 191, 964-968 (2005).
28. O. Sobolev, E. Binda, S. O'Farrell, A. Lorenc, J. Pradines, Y. Huang, J. Duffner, R. Schulz, J. Cason, M.Zambon, M. H.Malim, M.Peakman, A.Cope, I. Capila, G.V. Kaundinya, A. C. Hayday, Adjuvanted influenza-H1N1 vaccination reveals lymphoid signatures of age-dependent early responses and of clinical adverse events. Nat. Immunol. 17, 204-213 (2016).
29. S. L. Deshmane, S. Kremlev, S. Amini, B. E. Sawaya, Monocyte chemoattractant protein-1 (MCP-1): An overview. J. Interferon Cytokine Res. 29, 313-326 (2009).
30. T. Clahsen, F. Schaper, Interleukin-6 acts in the fashion of a classical chemokine on monocytic cells by inducing integrin activation, cell adhesion, actin polymerization, chemotaxis, and transmigration. J. Leukoc. Biol. 84, 1521-1529 (2008).
31. S. Iwamoto, S.-i. Iwai, K. Tsujiyama, C. Kurahashi, K. Takeshita, M. Naoe, A. Masunaga, Y. Ogawa, K. Oguchi, A. Miyazaki, TNF-A drives human CD14+ monocytes to differentiate into CD70+ dendritic cells evoking Th1 and Th17 responses. J. Immunol. 179, 1449-1457 (2007).
32. S. Perrier, F. Darakhshan, E. Hajduch, IL-1 receptor antagonist in metabolic diseases: Dr Jekyll or Mr Hyde? FEBS Lett. 580, 6289-6294 (2006).
33. H. Feldmann, H. Bugany, F. Mahner, H.-D. Klenk, D. Drenckhahn, H.-J. Schnittler, Filovirusinduced endothelial leakage triggered by infected monocytes/macrophages. J. Virol. 70, 2208-2214 (1996).
34. M. Yáñez-Mó, P. R.-M. Siljander, Z. Andreu, A. B. Zavec, F. E. Borrás, E. I. Buzas, K. Buzas, E. Casal, F. Cappello, J. Carvalho, E. Colás, A. Cordeiro-da Silva, S. Fais, J. M. Falcon-Perez, I. M. Ghobrial, B. Giebel, M. Gimona, M. Graner, I. Gursel, M. Gursel, N. H. H. Heegaard, A. Hendrix, P. Kierulf, K. Kokubun, M. Kosanovic, V. Kralj-Iglic, E.-M. Krämer-Albers, S. Laitinen, C. Lässer, T. Lener, E. Ligeti, A. Line, G. Lipps, A. Llorente, J. Lötvall, M. Manček-Keber, A. Marcilla, M. Mittelbrunn, I. Nazarenko, E. N. M. Noltet Hoen, T. A. Nyman, L. O'Driscoll, M. Olivan, C. Oliveira, É. Pállinger, H. A. del Portillo, J. Reventós, M. Rigau, E. Rohde, M. Sammar, F. Sánchez-Madrid, N. Santarém, K. Schallmoser, M. S. Ostenfeld, W. Stoorvogel, R. Stukelj, S. G. Van der Grein, M. H. Vasconcelos, M. H. Wauben, O. De Wever, Biological properties of extracellular vesicles and their physiological functions. J. Extracell. Vesicles 4, 27066 (2015).
35. A. C. Stanley, P. Lacy, Pathways for cytokine secretion. Physiology 25, 218-229 (2010).
36. T. Kawai, S. Akira, Innate immune recognition of viral infection. Nat. Immunol. 7, 131-137 (2006).
37. N. G. Dowell, E. A. Cooper, J. Tibble, V. Voon, H. D. Critchley, M. Cercignani, N. A. Harrison, Acute changes in striatal microstructure predict the development of interferon-Alpha induced fatigue. Biol. Psychiatry 79, 320-328 (2016).
38. K. L. Hokeness, W. A. Kuziel, C. A. Biron, T. P. Salazar-Mather, Monocyte chemoattractant protein-1 and CCR2 interactions are required for IFN-A/b-induced inflammatory responses and antiviral defense in liver. J. Immunol. 174, 1549-1556 (2005).
39. M. Luiza-Silva, A. C. Campi-Azevedo, M. A. Batista, M. Angela Martins, R. Sathler Avelar, D. da Silveira Lemos, L. A. B. Camacho, R. de Menezes Martins, M. de Lourdes Sousa Maia, R. H. Guedes Farias, M. da Silva Freire, R. Galler, A. Homma, J. G. Leite Ribeiro, J. A. Campos Lemos, M. Auxiliadora-Martins, S. M. Eloi-Santos, A. Teixeira-Carvalho, O. A. Martins-Filho, Cytokine signatures of innate and adaptive immunity in 17DD yellow fever vaccinated children and its association with the level of neutralizing antibody. J. Infect. Dis. 204, 873-883 (2011).
40. T. D. Querec, R. S. Akondy, E. K. Lee, W. Cao, H. I. Nakaya, D. Teuwen, A. Pirani, K. Gernert, J. Deng, B. Marzolf, K. Kennedy, H. Wu, S. Bennouna, H. Oluoch, J. Miller, R. Z. Vencio, M. Mulligan, A. Aderem, R. Ahmed, B. Pulendran, Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat. Immunol. 10, 116-125 (2009).
41. H. I. Nakaya, T. Hagan, S. S. Duraisingham, E. K. Lee, M. Kwissa, N. Rouphael, D. Frasca, M. Gersten, A. K. Mehta, R. Gaujoux, G.-M. Li, S. Gupta, R. Ahmed, M. J. Mulligan, S. Shen-Orr, B. B. Blomberg, S. Subramaniam, B. Pulendran, Systems analysis of immunity to influenza vaccination across multiple years and in diverse populations reveals shared molecular signatures. Immunity 43, 1186-1198 (2015).
42. H. I. Nakaya, E. Clutterbuck, D. Kazmin, L. Wang, M. Cortese, S. E. Bosinger, N. B. Patel, D. E. Zak, A. Aderem, T. Dong, G. Del Giudice, R. Rappuoli, V. Cerundolo, A. J. Pollard, B. Pulendran, C.-A. Siegrist, Systems biology of immunity to MF59-Adjuvanted versus nonadjuvanted trivalent seasonal influenza vaccines in early childhood. Proc. Natl. Acad. Sci. U.S.A. 113, 1853-1858 (2016).
43. A. Schattner, A. Meshorer, D. Wallach, Involvement of interferon in virus-induced lymphopenia. Cell. Immunol. 79, 11-25 (1983).
44. J. E. Ledgerwood, A. D. DeZure, D. A. Stanley, L. Novik, M. E. Enama, N. M. Berkowitz, Z. Hu, G. Joshi, A. Ploquin, S. Sitar, I. J. Gordon, S. A. Plummer, L. A. Holman, C. S. Hendel, G. Yamshchikov, F. Roman, A. Nicosia, S. Colloca, R. Cortese, R. T. Bailer, R. M. Schwartz, M. Roederer, J. R. Mascola, R. A. Koup, N. J. Sullivan, B. S. Graham; VRC 207 Study Team, Chimpanzee adenovirus vector Ebola vaccine. N. Engl. J. Med. 376, 928-938 (2017).
45. F.-C. Zhu, L.-H. Hou, J.-X. Li, S.-P. Wu, P. Liu, G.-R. Zhang, Y.-M. Hu, F.-Y. Meng, J.-J. Xu, R. Tang, J.-L. Zhang, W.-J. Wang, L. Duan, K. Chu, Q. Liang, J.-L. Hu, L. Luo, T. Zhu, J.-Z. Wang, W. Chen, Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: Preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet 385, 2272-2279 (2015).
46. H. Kibuuka, N. M. Berkowitz, M. Millard, M. E. Enama, A. Tindikahwa, A. B. Sekiziyivu, P. Costner, S. Sitar, D. Glover, Z. Hu, G. Joshi, D. Stanley, M. Kunchai, L. A. Eller, R. T. Bailer, R. A. Koup, G. J. Nabel, J. R. Mascola, N. J. Sullivan, B. S. Graham, M. Roederer, N. L. Michael, M. L. Robb, J. E. Ledgerwood; RV 247 Study Team, Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: A phase 1b, randomised, double-blind, placebo-controlled clinical trial. Lancet 385, 1545-1554 (2015).
47. K. Ewer, T. Rampling, N. Venkatraman, G. Bowyer, D. Wright, T. Lambe, E. B. Imoukhuede, R. Payne, S. K. Fehling, T. Strecker, N. Biedenkopf, V. Krahling, C. M. Tully, N. J. Edwards, E. M. Bentley, D. Samuel, G. Labbé, J. Jin, M. Gibani, A. Minhinnick, M. Wilkie, I. Poulton, N. Lella, R. Roberts, F. Hartnell, C. Bliss, K. Sierra-Davidson, J. Powlson, E. Berrie, R. Tedder, F. Roman, I. De Ryck, A. Nicosia, N. J. Sullivan, D. A. Stanley, O. T. Mbaya, J. E. Ledgerwood, R. M. Schwartz, L. Siani, S. Colloca, A. Folgori, S. Di Marco, R. Cortese, E. Wright, S. Becker, B. S. Graham, R. A. Koup, M. M. Levine, A. Volkmann, P. Chaplin, A. J. Pollard, S. J. Draper, W. R. Ballou, A. Lawrie, S. C. Gilbert, A. V. S. Hill, A monovalent chimpanzee adenovirus Ebola vaccine boosted with MVA. N. Engl. J. Med. 374, 1635-1646 (2016).
48. I. D. Milligan, M. M. Gibani, R. Sewell, E. A. Clutterbuck, D. Campbell, E. Plested, E. Nuthall, M. Voysey, L. Silva-Reyes, M. J. McElrath, S. C. De Rosa, N. Frahm, K. W. Cohen, G. Shukarev, N. Orzabal, W. van Duijnhoven, C. Truyers, N. Bachmayer, D. Splinter, N. Samy, M. G. Pau, H. Schuitemaker, K. Luhn, B. Callendret, J. Van Hoof, M. Douoguih, K. Ewer, B. Angus, A. J. Pollard, M. D. Snape, Safety and immunogenicity of novel adenovirus type 26-And modified vaccinia ankara-vectored Ebola vaccines: A randomized clinical trial. JAMA 315, 1610-1623 (2016).
49. O. De Santis, R. Audran, E. Pothin, L. Warpelin-Decrausaz, L. Vallotton, G. Wuerzner, C. Cochet, D. Estoppey, V. Steiner-Monard, S. Lonchampt, A.-C. Thierry, C. Mayor, R. T. Bailer, O. T. Mbaya, Y. Zhou, A. Ploquin, N. J. Sullivan, B. S. Graham, F. Roman, I. De Ryck, W. R. Ballou, M. P. Kieny, V. Moorthy, F. Spertini, B. Genton, Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: A randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study. Lancet Infect. Dis. 16, 311-320 (2016).
50. M. D. Tapia, S. O. Sow, K. E. Lyke, F. C. Haidara, F. Diallo, M. Doumbia, A. Traore, F. Coulibaly, M. Kodio, U. Onwuchekwa, M. B. Sztein, R. Wahid, J. D. Campbell, M. P. Kieny, V. Moorthy, E. B. Imoukhuede, T. Rampling, F. Roman, I. De Ryck, A. R. Bellamy, L. Dally, O. T. Mbaya, A. Ploquin, Y. Zhou, D. A. Stanley, R. Bailer, R. A. Koup, M. Roederer, J. Ledgerwood, A. V. Hill, W. R. Ballou, N. Sullivan, B. Graham, M. M. Levine, Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: A phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial. Lancet Infect. Dis. 16, 31-42 (2016).
51. A. Marzi, S. J. Robertson, E. Haddock, F. Feldmann, P. W. Hanley, D. P. Scott, J. E. Strong, G. Kobinger, S. M. Best, H. Feldmann, VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain. Science 349, 739-742 (2015).
52. A. Marzi, H. Ebihara, J. Callison, A. Groseth, K. J. Williams, T. W. Geisbert, H. Feldmann, Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy. J. Infect. Dis. 204 (Suppl. 3), S1066-S1074 (2011).
53. A. M. Henao-Restrepo, I. M. Longini, M. Egger, N. E. Dean, W. J. Edmunds, A. Camacho, M. W. Carroll, M. Doumbia, B. Draguez, S. Duraffour, G. Enwere, R. Grais, S. Gunther, S. Hossmann, M. K. Kondé, S. Kone, E. Kuisma, M. M. Levine, S. Mandal, G. Norheim, X. Riveros, A. Soumah, S. Trelle, A. S. Vicari, C. H. Watson, S. Kéïta, M. P. Kieny, J.-A. Røttingen, Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: Interim results from the Guinea ring vaccination cluster-randomised trial. Lancet 386, 857-866 (2015).
54. T. Querec, S. Bennouna, S. Alkan, Y. Laouar, K. Gorden, R. Flavell, S. Akira, R. Ahmed, B. Pulendran, Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J. Exp. Med. 203, 413-424 (2006).
55. S. Li, N. Rouphael, S. Duraisingham, S. Romero-Steiner, S. Presnell, C. Davis, D. S. Schmidt, S. E. Johnson, A. Milton, G. Rajam, S. Kasturi, G. M. Carlone, C. Quinn, D. Chaussabel, A. K. Palucka, M. J. Mulligan, R. Ahmed, D. S. Stephens, H. I. Nakaya, B. Pulendran, Molecular signatures of antibody responses derived from a systems biology study of five human vaccines. Nat. Immunol. 15, 195-204 (2014).
56. C. Gabay, M. F. Smith, D. Eidlen, W. P. Arend, Interleukin 1 receptor antagonist (IL-1Ra) is an acute-phase protein. J. Clin. Invest. 99, 2930-2940 (1997).
57. A. Finnegan, C. D. Kaplan, Y. Cao, H. Eibel, T. T. Glant, J. Zhang, Collagen-induced arthritis is exacerbated in IL-10-deficient mice. Arthritis Res. Ther. 5, R18-R24 (2003).
58. D. K. Clarke, R. M. Hendry, V. Singh, J. K. Rose, S. J. Seligman, B. Klug, S. Kochhar, L. M. Mac, B. Carbery, R. T. Chen; Brighton Collaboration Viral Vector Vaccines Safety Working Group, Live virus vaccines based on a vesicular stomatitis virus (VSV) backbone: Standardized template with key considerations for a risk/benefit assessment. Vaccine 34, 6597-6609 (2016).
59. B. N. Fields, K. Hawkins, Human infection with the virus of vesicular stomatitis during an epizootic. N. Engl. J. Med. 277, 989-994 (1967).
60. J. D. Fuchs, I. Frank, N. Kochar, M. Elizaga, M. Allen, D. K. Carter, N. Frahm, S. A. Kalams, M. Mulligan, R. Sheets, M. Pensiero, D. K. Clarke, J. H. Eldridge, N. H. V. T. Network, paper presented at the 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Rome, 17 July 2011.
61. E. Muyanja, A. Ssemaganda, P. Ngauv, R. Cubas, H. Perrin, D. Srinivasan, G. Canderan, B. Lawson, J. Kopycinski, A. S. Graham, D. K. Rowe, M. J. Smith, D. Gaucher, S. Isern, S. Michael, G. Silvestri, T. H. Vanderford, E. Castro, G. Pantaleo, J. Singer, J. Gillmour, N. Kiwanuka, A. Nanvubya, C. Schmidt, J. Birungi, J. Cox, E. K. Haddad, P. Kaleebu, P. Fast, R.-P. Sekaly, L. Trautmann, Immune activation alters cellular and humoral responses to yellow fever 17D vaccine. J. Clin. Invest. 124, 3147-3158 (2014).
62. L. Lai, R. Davey, A. Beck, Y. Xu, A. F. Suffredini, T. Palmore, S. Kabbani, S. Rogers, G. Kobinger, J. Alimonti, C. J. Link Jr., L. Rubinson, U. Stroher, M. Wolcott, W. Dorman, T. M. Uyeki, H. Feldmann, H. C. Lane, M. J. Mulligan, Emergency postexposure vaccination with vesicular stomatitis virus-vectored Ebola vaccine after needlestick. JAMA 313, 1249-1255 (2015).
63. S. A. Joosten, J. J. Goeman, J. S. Sutherland, L. Opmeer, K. G. de Boer, M. Jacobsen, S. H. Kaufmann, L. Finos, C. Magis-Escurra, M. O. Ota, T. H. Ottenhoff, M. C. Haks, Identification of biomarkers for tuberculosis disease using a novel dual-color RT-MLPA assay. Genes Immun. 13, 71-82 (2012).
64. H. F. Kaiser, An index of factor simplicity. Psychometrika 39, 31-36 (1974).